ACTIVE

RNA Pioneering

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-128,2 k €-1,8 %over 1 year
Gross margin-111,5 k €-37,3 %over 1 year
Equity5,5 M €-2,3 %over 1 year

Identity

Source · BCE/KBO

RNA Pioneering is a Public limited company incorporated in 1995. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Gent.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0456.792.695
Incorporation
29/12/1995
Legal form
Public limited company
Registered office
Rijvisschestraat 120
9052 Gent · FlandreSee on map
Contributed capital
7 710 380,00 €
Latest accounts
31/12/2025
Joint committees (1)
  • 207
Signals
Solid equityLow riskGood liquidity

Financials

Source · NBB, 20 filings

Trend over 17 financial years

20252024202320222021
Income statement
Gross margin-111,5 k €-81,2 k €-314,3 k €207,3 k €838,3 k €
EBITDA-114,4 k €-82,4 k €-316 k €203,9 k €248,7 k €
Operating result-119,6 k €-123,8 k €-342 k €146,8 k €206,4 k €
Net result-128,2 k €-126 k €-350,3 k €145,6 k €205,8 k €
Balance sheet
Equity5,5 M €5,6 M €5,8 M €1,2 M €1 M €
Total assets5,6 M €5,7 M €5,8 M €1,2 M €1,2 M €
Cash198,5 k €35,2 k €111,2 k €110,5 k €338,1 k €
Debts117,8 k €35,8 k €74,2 k €10,1 k €177,7 k €
Other
Workforce––––0,9 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 22 ended

Active mandates

BELLEVUE

Director · since 28 juin 2022 · until 25 juin 2027 · 0841.241.408

Represented by Christiaan CARDON

Active

Ended mandates

BELLEVUE

Director · since 28 juin 2022 · until 25 juin 2027 · 0841.241.408

Represented by Christiaan CARDON

Ended
BELLEVUE

Managing director · since 28 juin 2022 · until 25 juin 2027 · 0841.241.408

Represented by Cardon CHRISTIAAN

Ended
BELLEVUE

Managing director · since 23 décembre 2021 · until 25 juin 2027 · 0841.241.408

Represented by Christiaan CARDON

Ended
SEASTAR CAPITAL

Director · since 29 octobre 2019 · until 29 octobre 2025 · 0685.867.204

Represented by Joost VAN CAUWENBERGE

Ended

Other companies at this address

Rijvisschestraat 120 9052 Gent
CompanyCBE no.
BELLEVUE● Active
0841.241.408
BORDEAUX I● Active
0839.861.632
CARDON BIO● Active
0782.633.810
CELL-CELL BIO● Active
0782.638.362
DOING WELL BY DOING GOOD● Active
0476.250.994
Ziphius● Active
0750.500.975

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date16/07/202627/08/202530/08/202428/09/202309/09/202230/11/2021
General meeting30/06/202625/08/202527/08/202429/08/202301/09/202206/04/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 20 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202530/06/202616/07/2026DutchPDF
Abridged model31/12/202425/08/202527/08/2025DutchPDF
Abridged model31/12/202327/08/202430/08/2024DutchPDF
Abridged model31/12/202229/08/202328/09/2023DutchPDF
Abridged model31/12/202101/09/202209/09/2022DutchPDF
Abridged model31/12/202006/04/202130/11/2021DutchPDF
Abridged model31/12/201908/09/202030/11/2020DutchPDF
Abridged model31/12/201828/06/201908/08/2019DutchPDF
Abridged model31/12/201729/06/201828/08/2018DutchPDF
Abridged model31/12/201630/06/201710/08/2017DutchPDF
Abridged model31/12/201529/11/201619/12/2016DutchPDF
Abridged model31/12/201430/06/201508/04/2016DutchPDF
Abridged model31/12/201327/06/201402/10/2014DutchPDF
Abridged model31/12/201220/09/201325/09/2013DutchPDF
Abridged model31/12/201130/06/201226/09/2012DutchPDF
Abridged model31/12/201030/06/201131/08/2011DutchPDF
Abridged model31/12/200913/12/201024/12/2010DutchPDF
Abridged model31/12/200829/06/200923/07/2009DutchPDF
Abridged model31/12/200729/06/200923/07/2009DutchPDF
Abridged model31/12/200629/06/200923/07/2009DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

1 active · 22 ended

Active mandates

BELLEVUE

Director · since 28 juin 2022 · until 25 juin 2027 · 0841.241.408

Represented by Christiaan CARDON

Active

Ended mandates

BELLEVUE

Director · since 28 juin 2022 · until 25 juin 2027 · 0841.241.408

Represented by Christiaan CARDON

Ended
BELLEVUE

Managing director · since 28 juin 2022 · until 25 juin 2027 · 0841.241.408

Represented by Cardon CHRISTIAAN

Ended
BELLEVUE

Managing director · since 23 décembre 2021 · until 25 juin 2027 · 0841.241.408

Represented by Christiaan CARDON

Ended
SEASTAR CAPITAL

Director · since 29 octobre 2019 · until 29 octobre 2025 · 0685.867.204

Represented by Joost VAN CAUWENBERGE

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Capital / shares14/07/2026
    KAPITAAL - AANDELEN
    PDF
  • Registered office31/10/2024
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Capital / shares31/01/2024
    KAPITAAL - AANDELEN
    PDF
  • Other02/05/2023
    BENAMING
    PDF
  • Mandates05/01/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates18/11/2019
    BENAMING - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares13/09/2019
    DOEL - KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Mandates06/09/2018
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-128,2 k €↓
  2. 2024
    Annual accounts 2024-126 k €↑
  3. 2023
    Annual accounts 2023-350,3 k €↓
  4. 2022
    Annual accounts 2022145,6 k €↓
  5. 2022
    Name changeRNA Pioneering
  6. 2021
    Annual accounts 2021205,8 k €↑
  7. 2021
    Name changeZiphius Therapeutics
  8. 2020
    Annual accounts 2020-596,3 k €↓
  9. 2018
    Annual accounts 2018328,9 k €↑
  10. 2015
    Annual accounts 201564,8 k €↑
  11. 2014
    Annual accounts 2014-7,8 k €↓
  12. 2013
    Annual accounts 201340,4 k €↑
  13. 2012
    Annual accounts 201233,9 k €↓
  14. 2011
    Annual accounts 2011402,7 k €↑
  15. 2010
    Annual accounts 2010100 k €↑
  16. 2009
    Annual accounts 200917,6 k €↓
  17. 2008
    Annual accounts 200882,3 k €↑
  18. 2007
    Annual accounts 2007-109,4 k €↓
  19. 2006
    Annual accounts 2006-56,8 k €
  20. 29/12/1995
    IncorporationPublic limited company